Drug
Dasabuvir clinical trials
Also written ABT-333.
Includes 2 studies of Dasabuvir sodium monohydrate.
- studies test it
- 46
- open now
- 0
- in phase 3
- 26
- first study started
- 2008
How studies write it
Studies that test it under each name
Development codes
- ABT-333
- 24
Studies by the year they started
46 studies that test it; most in 2015 (17)
| Year | Studies |
|---|---|
| 2008 | 2 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 3 |
| 2013 | 7 |
| 2014 | 6 |
| 2015 | 17 |
| 2016 | 3 |
| 2017 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 13
- Phase 3
- 26
- Phase 4
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 38 · Other 8
AbbVie (27) · AbbVie (prior sponsor, Abbott) (9) · Abbott (2) · Nova Scotia Health Authority (1) · Kirby Institute (1) · Humanity and Health Research Centre (1) · HaEmek Medical Center, Israel (1) · National Taiwan University Hospital (1)
Often tested with
Tested in the same studies.
Ritonavir (29) · Paritaprevir (28) · Ribavirin (28) · Ombitasvir (27) · Ombitasvir/Paritaprevir/Ritonavir (10) · Sofosbuvir (3) · Glecaprevir and pibrentasvir (1) · Ledipasvir, sofosbuvir drug combination (1)
Studies
Open first, then newest update. How each study uses dasabuvir is read from its arms, and is right about nine times in ten.
Testing it · 46
- Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV TreatmentActive, not recruitingPhase 4Nova Scotia Health AuthorityNCT02460133Written as Dasabuvir
- A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) InfectionCompletedPhase 3AbbVieNCT02219490Written as ABT-333
- Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/PCompletedPhase 3Kirby InstituteNCT02634008Written as Dasabuvir
- A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) InfectionCompletedPhase 3AbbVieNCT02167945Written as ABT-333
- Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral TherapyTerminatedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT02194998Written as Dasabuvir (DSV)
- A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric SubjectsCompletedPhase 2/3AbbVieNCT02486406Written as Dasabuvir
- DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)CompletedPhase 2/3Humanity and Health Research CentreNCT02555943Written as Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir
- A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced AdultsCompletedPhase 3AbbVie (prior sponsor, Abbott)NCT01715415Written as ABT-450/r/ABT-267, ABT-333
- A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected AdultsCompletedPhase 3AbbVieNCT02582632Written as dasabuvir
- A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated CirrhosisCompletedPhase 3AbbVie (prior sponsor, Abbott)NCT01704755Written as ABT-450/r/ABT-267, ABT-333
- A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and CirrhosisCompletedPhase 3AbbVieNCT02219503Written as Dasabuvir
- A Study to Evaluate Chronic Hepatitis C InfectionCompletedPhase 3AbbVie (prior sponsor, Abbott)NCT01716585Written as ABT-450/r/ABT-267, ABT-333
- A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 CoinfectionCompletedPhase 2/3AbbVieNCT01939197Written as ABT-333
- Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus InfectionCompletedPhase 3AbbVieNCT02609659Written as ombitasvir/paritaprevir/ritonavir and dasabuvir
- Proof of Concept Study To Evaluate the Efficacy and Justification Of OBV/PTV/r and DSV In Adults With Chronic Hepatitis C Virus Genotype 2K/1BCompletedPhase 4HaEmek Medical Center, IsraelNCT03050905Written as EXVIERA
- PrOD for Non-Cirrhotic Patients With HCV-1b Receiving HemodialysisCompletedPhase 4National Taiwan University HospitalNCT02874066Written as PTV/r/OBV/DSV
- A Study to Investigate HCV Response Rates in Real World Patients: HEARTLAND StudyCompletedPhase 4American Research CorporationNCT03710252Written as paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin
- ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated CirrhosisCompletedPhase 3AbbVieNCT02517528Written as ABT-333
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) InfectionCompletedPhase 2AbbVie (prior sponsor, Abbott)NCT00851890Written as ABT-333
- A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment BeforeCompletedPhase 3AbbVieNCT01854697Written as ABT-450/r/ABT-267, ABT-333
See all 46 studies that test dasabuvir →
Given in every arm · 7 — dasabuvir is usual care beside what is tested
- A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b InfectionCompletedPhase 3AbbVie (prior sponsor, Abbott)NCT01767116Written as ABT-450/r/ABT-267, ABT-333
- A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis CCompletedPhase 3AbbVie (prior sponsor, Abbott)NCT01674725Written as ABT-450/r/ABT-267, ABT-333
- A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)CompletedPhase 2AbbVieNCT01995071Written as ABT-450/r/ABT-267, ABT-333
- A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a InfectionCompletedPhase 3AbbVieNCT01833533Written as ABT-450/r/ABT-267, ABT-333
- Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected SubjectsCompletedPhase 2AbbVie (prior sponsor, Abbott)NCT01563536Written as ABT-333
- A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333CompletedPhase 1AbbottNCT00768690Written as ABT-333
- Bioavailability of ABT-333 Tablet Versus First in Human (FIH) Capsule Formulation and Safety, Tolerability and PK Study of Single Doses of ABT-333 in Healthy VolunteersCompletedPhase 1AbbottNCT00895102Written as ABT-333 Tablet
As the comparator · 1 — what is tested is compared with dasabuvir
Codes
What other systems call dasabuvir · ClinicalTrials.gg INT006487
- MeSH (NLM) C588260dasabuvirOne source NLM
- UNII (FDA) DE54EQW8T1DASABUVIRConfirmed FDA, NLM, Wikidata
- RxNorm 1597381Confirmed FDA, Wikidata
- Wikidata Q19462214dasabuvirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C123880DasabuvirOne source FDA
- DrugBank DB09183One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C588260 | dasabuvir | One source NLM |
| UNII (FDA) | DE54EQW8T1 | DASABUVIR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1597381 | — | Confirmed FDA, Wikidata |
| Wikidata | Q19462214 | dasabuvir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C123880 | Dasabuvir | One source FDA |
| DrugBank | DB09183 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.